- Home
- BOLD vs DYAI Comparison
BOLD vs DYAI Comparison
Compare BOLD & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- DYAI
- Stock Information
- Founded
- BOLD 2018
- DYAI 1979
- Country
- BOLD United States
- DYAI United States
- Employees
- BOLD N/A
- DYAI N/A
- Industry
- BOLD
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BOLD
- DYAI Health Care
- Exchange
- BOLD Nasdaq
- DYAI Nasdaq
- Market Cap
- BOLD 24.4M
- DYAI 28.3M
- IPO Year
- BOLD 2024
- DYAI 2004
- Fundamental
- Price
- BOLD $1.18
- DYAI $1.00
- Analyst Decision
- BOLD Buy
- DYAI Strong Buy
- Analyst Count
- BOLD 3
- DYAI 1
- Target Price
- BOLD $4.00
- DYAI $6.00
- AVG Volume (30 Days)
- BOLD 276.3K
- DYAI 63.2K
- Earning Date
- BOLD 08-11-2025
- DYAI 08-12-2025
- Dividend Yield
- BOLD N/A
- DYAI N/A
- EPS Growth
- BOLD N/A
- DYAI N/A
- EPS
- BOLD N/A
- DYAI N/A
- Revenue
- BOLD N/A
- DYAI $3,554,344.00
- Revenue This Year
- BOLD N/A
- DYAI $22.56
- Revenue Next Year
- BOLD N/A
- DYAI $30.95
- P/E Ratio
- BOLD N/A
- DYAI N/A
- Revenue Growth
- BOLD N/A
- DYAI 57.59
- 52 Week Low
- BOLD $1.00
- DYAI $0.91
- 52 Week High
- BOLD $4.72
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- DYAI 46.85
- Support Level
- BOLD N/A
- DYAI $0.91
- Resistance Level
- BOLD N/A
- DYAI $1.02
- Average True Range (ATR)
- BOLD 0.00
- DYAI 0.05
- MACD
- BOLD 0.00
- DYAI 0.01
- Stochastic Oscillator
- BOLD 0.00
- DYAI 35.07
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.